Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.
Reads0
Chats0
TLDR
Comparing the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast, colorectal, or prostate cancer is compared and the CTC definition used in these studies is reviewed.Abstract:
The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for new methods to monitor their use. Ideally, these modalities would be noninvasive, be independent of treatment, and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells (CTCs) shed into the blood during metastasis may satisfy this need. We developed the CellSearch System to enumerate CTC from 7.5 mL of venous blood. In this review we compare the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast (MBC), colorectal (MCRC), or prostate cancer (MPC) and review the CTC definition used in these studies. Evaluation of CTC at anytime during the course of disease allows assessment of patient prognosis and is predictive of overall survival.read more
Citations
More filters
Journal ArticleDOI
Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
Claudia Hille,Tobias M. Gorges,Sabine Riethdorf,Martine Mazel,Thomas Steuber,Gunhild von Amsberg,Frank König,Sven Peine,Catherine Alix-Panabières,Klaus Pantel +9 more
TL;DR: This work describes the establishment and technical validation of a novel ARV7 detection method integrating the CellSearch® technology, the only FDA-cleared CTC-enrichment method for metastatic prostate cancer available so far, and develops a highly sensitive and specific qPCR-based assay.
Journal ArticleDOI
A 65-nm CMOS Fully Integrated Analysis Platform Using an On-Chip Vector Network Analyzer and a Transmission-Line-Based Detection Window for Analyzing Circulating Tumor Cell and Exosome
Kiichi Niitsu,Taiki Nakanishi,Shunya Murakami,Maya Matsunaga,Atsuki Kobayashi,Nissar Mohammad Karim,Jun Ito,Naoya Ozawa,Tetsunari Hase,Hiromasa Tanaka,Mitsuo Sato,Hiroki Kondo,Kenji Ishikawa,Hidefumi Odaka,Yoshinori Hasegawa,Masaru Hori,Kazuo Nakazato +16 more
TL;DR: A fully integrated CMOS circuit based on a vector network analyzer and a transmission-line-based detection window for circulating tumor cell (CTC) and exosome analysis is presented for the first time.
Journal ArticleDOI
Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles
Guankui Wang,Halli Benasutti,Jessica F. Jones,Guixin Shi,Michael Benchimol,Sandeep C. Pingle,Santosh Kesari,Yasan Yeh,Li-En Hsieh,Yu-Tsueng Liu,Anthony D. Elias,Dmitri Simberg +11 more
TL;DR: Blood-stable MBs targeted to several surface markers for isolation of breast tumor cells were developed and can promote research and clinical applications involving primary tumors and metastases and multitargeted anti-human EpCAM/EGFR MBs bound all cell lines with over 95% efficiency.
Journal ArticleDOI
Single Small Extracellular Vesicle (sEV) Quantification by Upconversion Nanoparticles.
Guan Huang,Ying Zhu,Shi Miao Wen,Haoqi Mei,Yongtao Liu,Dejiang Wang,Mahnaz Maddahfar,Qian Peter Su,Gungun Lin,Yinghui Chen,Dayong Jin +10 more
TL;DR: A single-sEV enumeration platform using lanthanide-doped upconversion nanoparticles (UCNPs) is demonstrated, suitable for evaluating the heterogeneous antigen expression of sEV and can be easily adapted for biomarker discoveries and disease diagnosis.
Journal ArticleDOI
Circulating Tumor Cells: A Window to Understand Cancer Metastasis, Monitor and Fight Against Cancers
TL;DR: The importance of CTC study in understanding cancer metastasis and their potential clinical application as biomarkers to predict cancer progression and treatment response are discussed, as well as the current situation for CTC isolation and analysis.
References
More filters
Journal ArticleDOI
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
TL;DR: It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.